Avidity Biosciences, Inc.
CIK:
0001599901
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Large accelerated filer
State of Incorporation
DE
Business Address
3020 CALLAN ROAD, SAN DIEGO, CA, 92121
Mailing Address
3020 CALLAN ROAD, SAN DIEGO, CA, 92121
Phone
858-401-7900
Fiscal Year End
1231
EIN
461336960
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | February 27, 2026 | View on SEC |
| 4 Insider stock transaction report | February 27, 2026 | View on SEC |
| 4 Insider stock transaction report | February 27, 2026 | View on SEC |
| 4 Insider stock transaction report | February 27, 2026 | View on SEC |
| 4 Insider stock transaction report | February 27, 2026 | View on SEC |
| 4 Insider stock transaction report | February 27, 2026 | View on SEC |
| 4 Insider stock transaction report | February 27, 2026 | View on SEC |
| 8-K Current report of material events | February 27, 2026 | View on SEC |
| 4 Insider stock transaction report | February 27, 2026 | View on SEC |
| 4 Insider stock transaction report | February 27, 2026 | View on SEC |
Annual Reports
10-K
February 23, 2026
- Successfully advanced lead AOC program, AOC 1001 for DM1, into a Phase 3 clinical trial following positive Phase 2 data.
- Expanded clinical footprint by moving the AOC 1020 program for FSHD into Phase 1/2 development.
Material Events
8-K
Acquisition
February 26, 2026
High Impact
- Avidity Biosciences acquired by Novartis AG for approximately $6.5 billion, offering a significant premium to shareholders.
- Shareholders receive $50.00 per share, comprising $30.00 in cash and 0.5 shares of Novartis AG common stock.
8-K
Acquisition
February 23, 2026
High Impact
- Novartis AG is acquiring Avidity Biosciences, validating its RNA-based platform and lead clinical programs.
- Avidity shareholders will receive merger consideration (cash/Novartis stock) AND shares in the new independent company, Atrium Therapeutics.
Insider Trading
STRONG SELL
8 insiders
18 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.